Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058563 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
A Phase 3 study of Measles and Mumps, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 996
- Enrollment target
- 17
- Study locations
NCT02058563 is a Phase 3 study of Measles and Mumps that has completed, run by GlaxoSmithKline. The registered enrollment target is 996 participants, below the 2,487-participant average among 4 other Measles trials with a reported enrollment target (60% lower). The trial reports 17 study locations across 9 states.
The verdict
NCT02058563, a Phase 3 study of Measles and Mumps, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 996 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.
Interventions
- BIOLOGICAL Priorix®
- BIOLOGICAL Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
Study Locations (17)
Other
- GSK Investigational Site - Tartu
- GSK Investigational Site - Bratislava
- GSK Investigational Site - Dolný Kubín
- GSK Investigational Site - Dunajská Streda
- GSK Investigational Site - Martin
- GSK Investigational Site - Ružomberok
- GSK Investigational Site - Zlaté Moravce
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Mesa
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
Alabama
- GSK Investigational Site - Birmingham
Illinois
- GSK Investigational Site - Chicago
Minnesota
- GSK Investigational Site - Edina
Missouri
- GSK Investigational Site - St Louis
Ohio
- GSK Investigational Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 996 participants |
| Start Date | 2014-07-01 |
| Est. Completion | 2015-09-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058563
The ClinicalTrials.gov registry entry for NCT02058563 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 996 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,487-participant average among 4 other Measles trials with a reported enrollment target (60% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Measles appearing as the primary indexed condition, and to 2 interventions - of which Priorix® is the first listed.
NCT02058563 reports 17 study locations spanning 9 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT02058563 about?
NCT02058563 is a clinical study titled "Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older". The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.
What is the current status of trial NCT02058563?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 996 participants. The study started on 2014-07-01. Estimated completion is 2015-09-17.
What conditions does trial NCT02058563 study?
This clinical trial studies the following conditions: Measles, Mumps, Rubella.
What interventions are being tested in trial NCT02058563?
The interventions under investigation include: Priorix® (BIOLOGICAL), Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02058563?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02058563 being conducted?
This trial has 17 study locations across Alabama, Arizona, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Measles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
COMPLETED · Phase 3
-
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
COMPLETED · Phase 3
-
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
COMPLETED · NA
-
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.